EDEN PRAIRIE, Minn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Winnebago Industries, Inc. (NYSE: WGO), a leading outdoor recreation product manufacturer, plans to issue its first quarter fiscal 2026 financial results before the opening of the New York Stock Exchange on Friday, December 19, 2025. At 9:00 a.m. CT, the company will conduct a conference call hosted by Michael Happe, president and chief executive officer, and Bryan Hughes, senior vice president and chief financial officer. You are invited to listen to t ...

TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc., company (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the cannabis, beverage, and wellness industries, today released its 2025 Cannabis Holiday Gift Guide, showcasing Canadians’ top picks for gifting, entertaining, and seasonal celebrations. With cannabis now firmly embedded in Canada’s holiday culture, the guide arrives ahead of one of the industry’s busiest retail periods. Acc ...

TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Q-Gold Resources Ltd. (TSXV: QGR; OTCQB: QGLDF; Börse Frankfurt: QX9G) (“QGold” or the “Company”) is pleased to announce the appointment of Jamsheed Mehta to its Board of Directors, effective immediately. Mr. Mehta brings over 35 years of capital markets experience, including a distinguished 31-year tenure at BMO Capital Markets. During his time at BMO, he held several senior leadership roles, including Head of Canadian Equities, Derivatives, and ETFs, culminating ...

(Selskabsmeddelelse 35/2025) Følgende ændringer er gennemført i prospektet: Afdelingen Europa Trends KL er tilføjet i prospektet. Afdelingen starter sine aktiviteter den 8. december 2025. Afdelingen består af to andelsklasser: Europa Trends A DKKEuropa Trends W DKK d Oplysninger om afdelingen fremgår på side 31 i prospektet. Redaktionelle ændringer. Prospektet er vedhæftet og kan findes på www.sydinvest.dk. Med venlig hilsen Syd Fund Management A/S Tlf. 74 37 33 00 Attachment SI Prospekt 2025.12.04_Fin ...

Agreement advances renewable, RFNBO-certified hydrogen production in southern France.Partnership supports logistics and mobility decarbonization across the Provence-Alpes-Côte d’Azur region.Project expands Plug’s European footprint through collaboration with Hy2gen on green hydrogen solutions. SLINGERLANDS, N.Y., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the hydrogen economy, announced it has signed a letter of intent (LOI) with ...

Continues Multi-Year Portfolio Simplification StrategyANTIOCH, Tenn., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LKQ Corporation (Nasdaq: LKQ) today announced that it has commenced a process to explore the potential sale of its Specialty segment. “Our Specialty segment is a leading distributor of automotive, RV and marine parts and accessories in North America. It is a strong business supported by an exceptional team. To unlock its full potential, we initiated a strategic review earlier this year to evaluate opportu ...

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis expected in the second half of 2027Raised $296.5 million in gross proceeds from initial public offering and concurrent private placement completed in October 2025Cash, cash equivalents and short-term investments sufficient to fund operations through 2027 SAN FRANCISCO and BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- ...

Not for distribution by US newswire or in United States TORONTO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), is pleased to announce that the Company completed its previously announced non-brokered private placement (see press release dated November 24, 2025) for gross proceeds of $140,000 (the "Private Placement"). Investors in the Private Placement subscribed for 1,244,441 units ("Units") at a price of $0.1125 per Unit. Each Unit consisted of one common s ...

Core Insights - Denali Therapeutics and Royalty Pharma have entered into a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa, Denali's lead investigational therapy for mucopolysaccharidosis type II (MPS II) [1][4] - The FDA is currently reviewing a Biologics License Application (BLA) for accelerated approval of tividenofusp alfa, with a target date of April 5, 2026 [2] Company Overview - Denali Therapeutics is focused on developing biotherapeutics that can cross the blood-brain barrier using its proprietary TransportVehicle platform, aiming to address serious diseases including neurodegenerative and lysosomal storage disorders [6] - Royalty Pharma, established in 1996, is the largest buyer of biopharmaceutical royalties and funds innovation in the biopharmaceutical industry, collaborating with various entities from academic institutions to leading pharmaceutical companies [7] Transaction Details - The agreement stipulates an initial payment of $200 million from Royalty Pharma, with an additional $75 million contingent upon achieving EMA approval by December 31, 2029 [4] - Royalty Pharma will receive a 9.25% royalty on worldwide net sales of tividenofusp alfa, with payments ceasing upon reaching a multiple of 3.0x or 2.5x if achieved by Q1 2039 [4] Leadership Statements - Denali's CEO, Ryan Watts, expressed optimism about the partnership with Royalty Pharma, highlighting the potential of tividenofusp alfa for the Hunter community and the broader implications for the TransportVehicle platform [3] - Royalty Pharma's CEO, Pablo Legorreta, emphasized the innovative nature of tividenofusp alfa and its potential to address significant unmet needs in Hunter syndrome [3]

PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking model for how CDMOs and CROs can ...